Evidence map›Paper›PMID 36069064›Full record

Observational studyClinical infectious diseases : an official publication of the Infectious Diseases Society of America2023

Effect of Adopting the New Race-Free 2021 Chronic Kidney Disease Epidemiology Collaboration Estimated Glomerular Filtration Rate Creatinine Equation on Racial Differences in Kidney Disease Progression Among People With Human Immunodeficiency Virus: An Observational Study.

Anthony N Muiru, Erin Madden, Rebecca Scherzer, Michael A Horberg, Michael J Silverberg, Marina B Klein, Angel M Mayor, M John Gill, Sonia Napravnik, Heidi M Crane and 8 more

Open access · bronzeAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 10 institutions in 3 countries.

Anthony N MuiruKidney Health Research Collaborative, Department of Medicine, University of California, San Francisco, California, USA.ORCID 0000-0003-2622-9658
Erin MaddenKidney Health Research Collaborative, Department of Medicine, University of California, San Francisco, California, USA.
Rebecca ScherzerKidney Health Research Collaborative, Department of Medicine, University of California, San Francisco, California, USA.
Michael A HorbergKaiser Permanente Mid-Atlantic Permanente Research Institute, Rockville, Maryland, USA.ORCID 0000-0002-6971-7646
Michael J SilverbergKaiser Permanente Northern California, Oakland, California, USA.ORCID 0000-0001-9322-1395
Marina B KleinDivision of Infectious Diseases and Chronic Viral Illness Service, McGill University Health Centre, Montreal, Quebec, Canada.
Angel M MayorRetrovirus Research Center, Internal Medicine Department, Universidad Central del Caribe, School of Medicine, Bayamon, Puerto Rico, USA.
M John GillDepartment of Medicine, University of Calgary, Southern Alberta HIV Clinic, Calgary, Alberta, Canada.
Sonia NapravnikDivision of Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.ORCID 0000-0002-9032-3713
Heidi M CraneDivision of Allergy and Infectious Diseases, Center for AIDS Research, University of Washington, Seattle, Washington, USA.
Vincent C MarconiDivision of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.ORCID 0000-0001-8409-4689
John R KoetheDivision of Infectious Diseases, Vanderbilt University Medical Center, Nashville, Tennessee, USA.ORCID 0000-0001-6490-6942
Alison G AbrahamDepartment of Epidemiology, School of Public Health University of Colorado, Anschutz Medical Campus, Aurora, Colorado, USA.
Keri N AlthoffDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.ORCID 0000-0002-5068-6595
Gregory M LucasDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Richard D MooreDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Michael G ShlipakKidney Health Research Collaborative, Department of Medicine, University of California, San Francisco, California, USA.
Michelle M EstrellaKidney Health Research Collaborative, Department of Medicine, University of California, San Francisco, California, USA.
University of California, San Francisco · USJohns Hopkins University · USKaiser Permanente · USCentral University of the Caribbean · PREmory University · USMcGill University Health Centre · CAUniversity of Calgary · CAUniversity of North Carolina at Chapel Hill · USUniversity of Washington · USVanderbilt University Medical Center · US

Funding

Epidemiology /Natural History--Cancer-Associated VirusesZ01CP010176 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI MBULAITEYE, SAM M · 2001 to 2008
$11.3M
Treatment outcomes and comorbidity in HIV-infected IDUK24DA035684 · NIDA · JOHNS HOPKINS UNIVERSITY · PI LUCAS, GREGORY M · 2014 to 2024
$1.5M
SEARCH-CKD: The nature of chronic kidney disease and elevated blood pressure in sub-Saharan Africa.K23DK119562 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MUIRU, ANTHONY N · 2021 to 2025
$1.0M
Intramural NIH HHS Z01 CP010176NIDA NIH HHS K24 DA035684NIDDK NIH HHS K23 DK119562
6 · The paper itself

Abstract

backgroundThe impact of adopting a race-free estimated glomerular filtration rate (eGFR) creatinine (eGFRcr) equation on racial differences in chronic kidney disease (CKD) progression among people with human immunodeficiency virus (PWH) is unknown.

methodsWe defined eGFR stages using the original race-adjusted Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) eGFRcr equation and the new race-free CKD-EPI eGFRcr equation. We then estimated 5-year probabilities of transitioning from baseline kidney function to more advanced eGFR stages and examined the association of race (black vs white) with rates of CKD progression using Markov models.

resultsWith the race-adjusted eGFRcr equation, black participants (n = 31 298) had a lower risk of progressing from eGFR stage 1 to 2 (hazard ratio [HR], 0.77; 95% confidence interval [CI], .73-.82), an equal risk of progressing from stage 2 to 3 (1.00; .92-.07) and a 3-fold risk of progressing from stage 3 to 4 or 5 (3.06; 2.60-3.62), compared with white participants (n = 27 542). When we used the race-free eGFRcr equation, 16% of black participants were reclassified into a more severe eGFR stage at baseline. The reclassified black individuals had a higher prevalence of CKD risk factors than black PWH who were not reclassified. With the race-free eGFRcr equation, black participants had a higher risk of disease progression across all eGFR stages than white participants.

conclusionsThe original eGFRcr equation systematically masked a subgroup of black PWH who are at high-risk of CKD progression. The new race-free eGFRcr equation unmasks these individuals and may allow for earlier detection and management of CKD.

Indexed as

HIV InfectionsRenal Insufficiency, ChronicBlack or African AmericanCreatinineDisease ProgressionGlomerular Filtration RateHumansKidneyRace FactorsWhiteCreatinineCKDeGFRESKDHIVrace

Identifiers

PMID36069064
PMCPMC10169400
OpenAlexW4294919176

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.